Subscribe
17 November 2017Big Pharma

Eli Lilly refused injunction against Teva, Actavis and Mylan

The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Teva and Alder sign deal to overcome antibodies dispute
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.
Americas
Teva goes to war with Eli Lilly over migraine breakthrough
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Americas
Bausch Health settles generic dispute with Actavis
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Biotechnology
Teva and Alder sign deal to overcome antibodies dispute
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.
Americas
Teva goes to war with Eli Lilly over migraine breakthrough
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Americas
Bausch Health settles generic dispute with Actavis
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).

More on this story

Biotechnology
Teva and Alder sign deal to overcome antibodies dispute
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.
Americas
Teva goes to war with Eli Lilly over migraine breakthrough
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Americas
Bausch Health settles generic dispute with Actavis
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages